Thrombotic microangiopathy with targeted cancer agents

Area of Science:

• Oncology
• Hematology
• Toxicology

Background:

• Thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS) are serious conditions with overlapping symptoms.
• These thrombotic microangiopathies (TMA) can arise from various causes, including chemotherapy.
• Emerging data links targeted cancer agents to TMA development.

Purpose of the Study:

• To review the clinical presentation, outcomes, and potential causes of TMA associated with targeted cancer agents.
• To compare TMA associated with targeted agents to chemotherapy-induced TMA.
• To highlight the need for monitoring and further research.

Main Methods:

• Literature search of PubMed and meeting abstracts for TMA cases linked to targeted cancer agents.
• Compilation of data on symptoms, laboratory values, onset, and outcomes.
• Analysis of findings in comparison to existing TMA literature.

Main Results:

• TMA presentation with targeted agents necessitates monitoring for renal toxicity, hemolysis, and thrombocytopenia.
• Outcomes appear distinct from chemotherapy-induced TMA, suggesting different etiologies.
• Partial to full reversibility of TMA may be more common with targeted agents.

Conclusions:

• TMA associated with targeted cancer agents requires vigilant monitoring for specific toxicities.
• The distinct outcomes suggest a different pathogenesis compared to chemotherapy-induced TMA.
• Further research is essential for optimizing management strategies for TMA in patients receiving targeted therapies.